Liquid Encapsulation Utilizing An Emulsion Or Dispersion To Form A Solid-walled Microcapsule (includes Liposome) Patents (Class 264/4.1)
  • Patent number: 11891436
    Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: February 6, 2024
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jörg Wischhusen, Markus Junker, Thomas Müller, Stefan Saremba
  • Patent number: 11890376
    Abstract: The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with a 0.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: February 6, 2024
    Assignee: Breath Therapeutics, GmbH
    Inventor: Oliver Denk
  • Patent number: 11884539
    Abstract: Methods and systems for high-speed production of nanoparticles with very high product yields are described. Systems utilize concentric micro-scale capillaries arranged to define nanoparticle formation regions that lie along predetermined length(s) of the capillaries. Flow through the formation regions can be laminar during a formation protocol. The system can include on-line analytical tools for real time characterization of products or intermediates. Systems include an additive manufacturing-type deposition at the terminus of the formation section. The deposition area includes a print head and a print bed and provides for random or patterned deposition of nanoparticles. The print head and/or the print bed can be capable of motion in one or more degrees of freedom relative to one another.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: January 30, 2024
    Assignee: Battelle Savannah River Alliance, LLC
    Inventors: Simona E. Hunyadi Murph, Vahid Majidi
  • Patent number: 11883398
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: January 30, 2024
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Patent number: 11874276
    Abstract: Provided herein are Stimulator of Interferon Genes (STING) and Stimulated 3 Prime Antisense Retroviral Coding Sequences (SPARCS) genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 16, 2024
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: David Barbie, Israel Cañadas, Shunsuke Kitajima, Thanh Barbie
  • Patent number: 11860076
    Abstract: The present invention relates to methods and systems for isolation of species in semi-permeable capsules and processing of encapsulated species through series of steps and/or reactions. To produce capsules, first aqueous two-phase system (ATPS) droplets are generated using microfluidics system and then the hydrogel shell layer is hardened by inducing polymerization. As exemplified in this invention to achieve concentric ATPS droplet formation density-matched PEGDA and Dextran polymer solutions can be used. Once a capsule is formed, its composition can be changed by adding new reagents or replacing out old ones (e.g. by resuspending capsules in desired aqueous solution). The hydrogel shell of semi-permeable capsules can be dissolved at selected step during multi-step procedures in order to release the encapsulated species. The present invention exemplifies the isolation of individual cells within capsules and using the encapsulated cells for genotypic and phenotypic analysis.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: January 2, 2024
    Assignees: Vilnius University, Droplet Genomics
    Inventors: Linas Mazutis, Greta Stonyte, Karolis Leonavicius, Ausra Zelvyte
  • Patent number: 11840702
    Abstract: An adenovirus comprising a sequence of formula (I) 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein BY comprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: December 12, 2023
    Assignee: AKAMIS BIO LIMITED
    Inventors: Brian Champion, Alice Claire Noel Bromley
  • Patent number: 11819574
    Abstract: Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: November 21, 2023
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Kathleen D. A. Los
  • Patent number: 11819575
    Abstract: Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: November 21, 2023
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Kathleen D. A. Los
  • Patent number: 11813279
    Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 14, 2023
    Assignee: AIM ImmunoTech Inc.
    Inventors: David R. Strayer, Thomas K. Equels
  • Patent number: 11788069
    Abstract: Disclosed herein are means for the detection and characterization of neurotoxins such as botulinum neurotoxin (BoNT) or tetanus neurotoxin. The present disclosure provides methods for determining potency and activity of neurotoxins in vitro and in vivo. Also disclosed are polypeptides comprising N- and C-terminal fragments of a reporter protein that are split by a linker comprising a neurotoxin cleavage site. Cleavage of the linker by a neurotoxin decreases reporter protein activity, thereby indicating activity of the neurotoxin. Compositions and kits comprising the disclosed polypeptides, nucleic acids comprising nucleotide sequences encoding such polypeptides, and cells expressing such polypeptides are also disclosed.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: October 17, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Min Dong, Feifan Yu
  • Patent number: 11779601
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 10, 2023
    Assignees: Kite Pharma, Inc., The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Patent number: 11753478
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 12, 2023
    Assignee: ABLEXIS, LLC
    Inventors: John Lippincott, Dana Duey
  • Patent number: 11753452
    Abstract: Embodiments of the present disclosure relate to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 12, 2023
    Inventors: Khaddouj Benmoussa, Elsa Bonnafe, Agnès Coste, Jérôme Leprince, Bernard Pipy, Michel Treilhou
  • Patent number: 11737981
    Abstract: Nanoparticles including a cellulosic polymer and a hydrophobic material and methods for forming them.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: August 29, 2023
    Assignee: The Trustees of Princeton University
    Inventors: Robert K. Prud'Homme, Jie Feng, Kurt D. Ristroph, Hoang (Jack) Lu, Yingyue Zhang, Simon A. McManus, Robert F. Pagels
  • Patent number: 11707421
    Abstract: The present specification discloses compositions comprising one or more encapsulates comprising one or more agents and methods and uses for the disclosed agents. A composition disclosed herein can be incorporated into a body wash, an after shower body lotion, a shampoo, a conditioner, a soap, a gel, a hand sanitizer, a cream, a spray, a mouse, a lotion, an ointment, a make-up product, a lip balm, a hair spray product, an arachnid/insect repellent or a medicinal product.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 25, 2023
    Assignee: CoLabs Int'l Corp.
    Inventors: Daniel H. Traynor, Laura E. Cohen
  • Patent number: 11707737
    Abstract: Engineered nanoscale multicomponent particles are introduced and are called “quants.” Methods and apparatuses for producing such multicomponent nanoparticles are provided. A single quant can be manufactured to contain a variety of different internal component molecules. Likewise, a plurality of such quants may be manufactured wherein the plurality of quants are suspended in an aqueous solution. Typically, quants are produced in quantity and concentration adequate to support human scale therapeutics. In some embodiments, millions or billions of quants are suspended in a volume of aqueous solution for delivery to a patient. When manufactured to the same specification, the plurality of quants are uniform in size, uniform in chemical composition, and therefore uniform in functionality. Functional uniformity is an essential aspect of quants, manifested in design and production.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: July 25, 2023
    Inventor: Mark A. Gray
  • Patent number: 11692070
    Abstract: This document describes a process of producing gel microparticles, which are consistent in size and morphology. Through the process of coacervation, large volumes of gel microparticle slurry can be produced by scaling up reactor vessel size. Particles can be repeatedly dehydrated and rehydrated in accordance to their environment, allowing for the storage of particles in a non-solvent such as ethanol. Gel slurries exhibit a Bingham plastic behavior in which the slurry behaves as a solid at shear stresses that are below a critical value. Upon reaching the critical shear stress, the slurry undergoes a rapid decrease in viscosity and behaves as a liquid. The rheological behavior of these slurries can be adjusted by changing the compaction processes such as centrifugation force to alter the yield-stress. The narrower distribution and reduced size of these particles allows for an increase in FRESH printing fidelity.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: July 4, 2023
    Assignee: Carnegie Mellon University
    Inventors: Andrew Hudson, Thomas Hinton, Adam Feinberg, Andrew Lee
  • Patent number: 11673919
    Abstract: The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the I?B kinase ?/? (IKK?/?)-binding domain of NF-?B essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKK? interaction, thereby selectively inhibiting canonical NF-?B signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: June 13, 2023
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Patent number: 11673927
    Abstract: The present invention aims to provide a peptide of the C region of HGS and an antitumor agent comprising the same having a higher tumor growth inhibitory effect as compared with conventional techniques. An antitumor agent comprising a peptide comprising at least 10 consecutive amino acid residues of the amino acid sequence of the C region of HGS is described.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 13, 2023
    Assignee: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventor: Kiyoshi Ogura
  • Patent number: 11660270
    Abstract: Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: May 30, 2023
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Domb Abraham Jacob, Michael Kubek
  • Patent number: 11648522
    Abstract: An improved process of forming polyurea and chitosan microcapsules encapsulating a benefit agent is described. The process comprises forming a water phase comprising hydrolyzing chitosan in an acidic medium at a pH of 6.5 or less for an extended period and combining with a polyisocyanate. The reaction product of the hydrolyzed chitosan and polyisocyanate yields a microcapsule having improved release characteristics, with enhanced degradation characteristics in OECD test method 301B.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: May 16, 2023
    Assignee: Encapsys, LLC
    Inventor: Linsheng Feng
  • Patent number: 11638695
    Abstract: The present invention provides a method for producing lipid particles that have a desired particle diameter, the method comprising: (A) a step for preparing, in a first mixing region, a primary dilution by mixing a first solution containing a lipid and an alcohol with a second solution containing water; (B) a step for feeding the primary dilution from the first mixing region to a second mixing region through a liquid feed pipe within a prescribed time; and (C) a step for preparing a secondary dilution by mixing the primary dilution with a third solution containing water in the second mixing region, wherein the steps (A)-(C) are continuously carried out, and the particle diameter of the lipid particles is controlled by adjusting at least one condition selected from the group consisting of the concentration of the alcohol and the concentration of the lipid in the primary dilution, the prescribed time, and the temperature during mixing.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 2, 2023
    Assignee: OSAKA UNIVERSITY
    Inventor: Takashi Matsuzaki
  • Patent number: 11633360
    Abstract: The present invention relates to a method for preparing biodegradable microspheres using a single-phase mixed solution containing water, alcohol, and dichloromethane. Provided is a method for preparing a biodegradable microsphere having a uniform drug loading efficiency by preparing and using a single-phase mixed solution in which no phase separation occurs without using a thickener and a surfactant. The preparation method of the present invention has the feature of keeping the content of a loaded drug uniform until a final biodegradable microsphere is prepared, by using a single-phase mixed solution in which no phase separation by a solvent occurs in the preparation process. Thus, the preparation method of the present invention is remarkably useful for the preparation of biodegradable microspheres.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: April 25, 2023
    Assignee: HLB PHARMACEUTICAL CO., LTD
    Inventors: Sang Hwi Lee, Mijung Kim, Dooyong Jeong, Mi Jung Kim, Wan Joo Kim, So Kyoung Joo
  • Patent number: 11590231
    Abstract: The present invention relates to compositions and methods for enhancing bioavailability of health-promoting substances, such as pharmaceuticals and nutritional supplements. The subject invention utilizes an adjuvant composition comprising one or more microbial-produced biosurfactants and/or isoforms thereof, to enhance bioavailability of health-promoting substances and to reduce the effective dosage that is required.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: February 28, 2023
    Assignee: LOCUS SOLUTIONS IPCO, LLC
    Inventors: Andrew R. Lefkowitz, Sean Farmer, Ken Alibek
  • Patent number: 11571385
    Abstract: The present invention relates to a self-emulsifiable composition including a monoacyl phospholipid, a diacyl phospholipid, oils and fats, and a polyhydric alcohol, in which the content ratio between the monoacyl phospholipid and the diacyl phospholipid is in the range of monoacyl phospholipid:diacyl phospholipid=1:9 to 9:1 as a mass ratio.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 7, 2023
    Assignee: Kewpie Corporation
    Inventor: Yohei Amano
  • Patent number: 11559543
    Abstract: Provided is an immunostimulator containing: chitosan and/or a chitosan derivative each having a weight-average molecular weight of 10k to 1000k; and an anionic surfactant, the immunostimulator being in particulate form. Also provided are a pharmaceutical composition and an alimentary product, each containing the immunostimulator as an active ingredient.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: January 24, 2023
    Assignee: ZENOGEN PHARMA CO., LTD.
    Inventors: Etsuya Okamoto, Hiroaki Kodama
  • Patent number: 11560414
    Abstract: Disclosed are compositions comprising myokines and their methods of preparation and use. The disclosed myokine compositions and methods may comprise myokines having a molecular weight of greater than about 10 kDa such as myostatin and metrnl. The disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders. In particular, the disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders, such as cancer, and metabolic diseases and disorders, such as diabetes, non-alcoholic fatty liver disease, and heart disease.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 24, 2023
    Assignee: Northwestern University
    Inventors: Hemant K. Roy, Vadim Backman
  • Patent number: 11559486
    Abstract: Disclosed herein are various compositions comprising neoplastic formulations and their methods of use.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 24, 2023
    Assignee: Acrotech Biopharma, LLC
    Inventors: William T. Monte, Robert Malcolm Abra, Bing Luo, Yuanpeng Zhang
  • Patent number: 11559482
    Abstract: The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: January 24, 2023
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Ulrich Hersel, Mathias Krusch, Dirk Vetter, Tobias Voigt
  • Patent number: 11542311
    Abstract: The invention discloses a fusion protein, a preparation method thereof and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament, and belongs to the field of biopharmaceutical technology. The present invention uses a flexible (F) or rigid (R) linker to fuse two polypeptides to respectively obtain two bifunctional fusion proteins, namely two multi-functional fusion protein macromolecules obtained by linking antiangiogenesis polypeptides HM-3, interleukin 4 and immunoglobulin Fc fragments via an amino acid linker, which can improve drug efficacy, prolong half-life and enhance stability, has the characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammations and neovascular ophthalmic diseases. The fusion protein is expressed in a eukaryotic cell by a genetic engineering method and purified by affinity chromatography or the like.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: January 3, 2023
    Assignee: JIANGSU RONGTAI BIOTECH CO., LTD.
    Inventor: Hanmei Xu
  • Patent number: 11535718
    Abstract: A method for preparing a color masterbatch with a natural dye is disclosed. The new method uses a phase change material tetradecane as one of the solvents to extract the natural dye, the extracted natural dye as a core material, and polybutylene succinate as a wall material to microencapsulate the natural dye containing the phase change material by a solvent evaporation method to prepare natural dye microcapsules, then melt-blends with a carrier resin, extrudes and granulates to obtain the color masterbatch with the natural dye. The microencapsulation improves the thermal stability of natural dye and compatibility with carrier resin The obtained color masterbatch with natural dye has excellent heat resistance, and the fabric obtained after spinning with it has good color fastness to hot pressing.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: December 27, 2022
    Assignee: CHANGZHOU UNIVERSITY
    Inventors: Qun Chen, Yonggang Peng, Junling Ji, Haiqun Chen, Yuan Wang, Junjie Tan
  • Patent number: 11529403
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: December 20, 2022
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Patent number: 11518819
    Abstract: The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: December 6, 2022
    Assignee: TRICAN BIOTECHNOLOGY CO., LTD
    Inventors: Huang-Tsu Chen, Jiun-Shyang Leou, Chung-Yuan Hsu, Cheng-Ke Li, Yun-Ting Wang, Li-Tsen Lin
  • Patent number: 11511253
    Abstract: Provided is a method of fabricating capsules. The method includes: forming droplets of a dispersed phase solution including a phase transition material, a carbon nanomaterial, and a first monomer by allowing the dispersed phase solution to pass through nozzle units provided at a porous membrane in a reaction tank including the porous membrane; migrating the droplets into a mobile phase material including a second monomer; and forming polymer shells at interfaces between the droplets and the mobile phase material by polymerization between the first monomer and the second monomer.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: November 29, 2022
    Assignee: Korea Institute of Science and Technology
    Inventors: Sun Choi, Youngkyun Jung, Ung Su Choi
  • Patent number: 11497715
    Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 15, 2022
    Assignee: Cureport, Inc.
    Inventor: De-Min Zhu
  • Patent number: 11497692
    Abstract: Cosmetic blending devices for producing a cosmetic liquid from a solid-shell cosmetic ingredient capsule. The cosmetic blending devices include a lid, a base, a blending element configured to blend the capsule, and a drive mechanism configured to actuate the blending element. The cosmetic blending device may include a thermal element configured to change a temperature of the capsule. The thermal element may melt the capsule. The solid-shell cosmetic ingredient capsule comprises a shell defining an enclosed inner volume, and cosmetic material included in the enclosed inner volume. Methods of using the cosmetic blending devices comprise placing the solid-shell cosmetic ingredient capsule into the cosmetic blending device and blending the capsule to produce the cosmetic liquid. Methods of forming the solid-shell cosmetic ingredient capsule comprise forming a portion of the shell, adding the cosmetic material to the portion of the shell, and forming the remaining portion of the shell.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: November 15, 2022
    Assignee: REA Innovations, Inc.
    Inventors: Robb Akridge, Gregory Calvin Peterson
  • Patent number: 11466089
    Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: October 11, 2022
    Assignee: Ablynx N.V.
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Patent number: 11446336
    Abstract: The invention provides a composition comprising a bacterial strain of the genus Parabacteroides, for use in a method of treating or preventing cancer in a subject; wherein the cancer comprises oncogenic ERK signalling.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: September 20, 2022
    Assignee: 4D Pharma Research Limited
    Inventors: Imke Elisabeth Mulder, Anna Ettorre, Suaad Ahmed, Parthena Fotiadou
  • Patent number: 11439579
    Abstract: The present invention concerns a sphere, characterized in that it comprises at least one polymer of hyaluronate and glucomannan. It also concerns a polymer of hyaluronate and glucomannan characterized in that each bond between a hyaluronate group and a glucomannan group is an ester bond. In addition, it concerns their production process and their use, in particular as a filling or hydration agent.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: September 13, 2022
    Assignee: BASF Beauty Care Solutions France SAS
    Inventors: Isabelle Bonnet, Florent Durieux, Eric Nappi
  • Patent number: 11439684
    Abstract: Provided herein are materials and methods for assessing ratios of lymphocyte to monocytes in cancer patients and, based on the ratios, treating the cancer patients with an immunotherapeutic.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 13, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Luis F. Porrata, Svetomir N. Markovic
  • Patent number: 11439698
    Abstract: The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: September 13, 2022
    Assignee: Arytha Biosciences, LLC
    Inventor: Che-Ming Jack Hu
  • Patent number: 11433086
    Abstract: Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C—X—C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: September 6, 2022
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, William E. Fogler
  • Patent number: 11419819
    Abstract: The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with a 0.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: August 23, 2022
    Inventor: Oliver Denk
  • Patent number: 11413329
    Abstract: The present invention is directed to cancer cell traps and methods of using cancer cell traps to treat and detect metastatic cancer in subjects. The cancer cell traps are administered to subjects and induce the migration and accumulation of metastatic cancer cells in the cancer cell traps.
    Type: Grant
    Filed: October 19, 2013
    Date of Patent: August 16, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Liping Tang
  • Patent number: 11401312
    Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: August 2, 2022
    Assignees: Cytune Pharma, Institut Gustave Roussy (IGR)
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • Patent number: 11395802
    Abstract: Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 26, 2022
    Assignees: Auburn University, Altimmune, Inc.
    Inventors: Allan E. David, Henry J. Baker, Aime K. Johnson, M. Scot Roberts, Kent R. Van Kampen, Prachi Sangle
  • Patent number: 11388907
    Abstract: A method of preparing a lysolecithin composition. The method includes the steps of (a) providing a lecithin mixture including a lecithin, water, and ethanol, (b) adding phospholipase A1 or A2 to the lecithin mixture; and (c) allowing an enzymatic reaction to occur so that at least 70% of the phospholipids in the lecithin are converted to lysophospholipids to obtain the lysolecithin composition. Also disclosed are a lysolecithin composition thus prepared, a flavor emulsion prepared from the lysolecithin composition, and a liquid beverage or liquid beverage concentrate containing the lysolecithin composition.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: July 19, 2022
    Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Ying Yang, Daniel Kaiping Lee, Chii-Fen Wang
  • Patent number: 11384120
    Abstract: The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 12, 2022
    Assignee: NIBEC CO., LTD.
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee
  • Patent number: 11382754
    Abstract: The present invention provides a technological platform for bone regeneration. More specifically, the invention provides an implant comprising a plurality of polymeric casings at least one of which encases a bone void filler and at least one reinforcement component. Also provided is a method of regenerating bone by implanting one or more implants according to the present invention to a bone repair site.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 12, 2022
    Assignee: TRACERAY OY
    Inventor: Yulia Kulkova